Purpose
Phase 3 development of the Islatravir (EFdA) monthly oral formulation
Grantee
Division
Global Health
Date
MARCH 2021
Region served
Committed amount
$122,264,513
Grant topic
HIV
Duration (months)
76
Grantee location
Seattle, Washington, United States
More about our work
Our work
Learn about where we work around the globe and the programs we’ve created to address urgent issues in global health, global development, and education.
How we work
We are focused on results. Those that can be measured. And those measured in ways beyond numbers.